EUVIMEDEUVIMED entdecken
Crossref

Bone Marrow Homing and GPRC5D‐Targeting Engineered Cell Membrane‐Camouflaged Hypoxia‐Responsive Nanoparticles for Multiple Myeloma Therapy

Bingyang Chu, Shiqian Li, Xue Wei, Xia Wu, Peipei Yang, Mengran Chen, Feng Zhang, Fangfang Wang, Jingcao Huang, Xinyu Zhai, Xijing Yang, Yuhuan Zheng und 4 weitere

Advanced Functional Materials · 2026-07 · 36 (57)

DOI: 10.1002/adfm.202532144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 21.06.2026. Verfasst von Bingyang Chu und 15 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is the second most common hematologic malignancy, characterized by malignant proliferation of plasma cells in the bone marrow. The bone marrow barrier limits the drug accumulation following conventional systemic administration, leading to incomplete tumor eradication. Thus, there is an urgent need to develop drug delivery systems capable of enhancing bone marrow accumulation and enabling precise recognition and efficient elimination of myeloma cells. Herein, genetically engineered myeloma cell membranes expressing anti‐GPRC5D single‐chain variable fragment (scFv) (aG‐MM) are employed to cloak bortezomib (BTZ)‐loaded hypoxia‐responsive nanoparticles (BTZ‐hr‐NPs). The resulting aG‐MM@BTZ‐hr‐NPs enable stepwise targeting: first, by mimicking the intrinsic bone marrow homing behavior of MM cells to facilitate nanoparticles accumulation within the bone marrow; and subsequently, through anti‐GPRC5D scFv‐mediated specific recognition of GPRCD5‐positive MM cells to enhance cellular uptake. Upon exposure to the hypoxic MM microenvironment, the nanoparticles undergo rapidly disintegration, triggering accelerated BTZ release. The released BTZ effectively inhibits proteasome activity, promoting apoptosis and modulating NF‐κB signaling, ultimately leading to MM cell death. In an orthotopic MM mouse model, aG‐MM@BTZ‐hr‐NPs effectively suppresses tumor progression. This genetically engineered, stimuli‐responsive nanoplatform providing a promising strategy of efficient targeted drug delivery and MM therapy.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Chu, B., Li, S., Wei, X., Wu, X., Yang, P., Chen, M., Zhang, F., Wang, F., Huang, J., Zhai, X., Yang, X., Zheng, Y., Niu, T., Zhang, K., Qu, Y., & Qian, Z. (2026). Bone Marrow Homing and GPRC5D‐Targeting Engineered Cell Membrane‐Camouflaged Hypoxia‐Responsive Nanoparticles for Multiple Myeloma Therapy. Advanced Functional Materials, 36(57). https://doi.org/10.1002/adfm.202532144

Vancouver

Chu B, Li S, Wei X, Wu X, Yang P, Chen M, et al. Bone Marrow Homing and GPRC5D‐Targeting Engineered Cell Membrane‐Camouflaged Hypoxia‐Responsive Nanoparticles for Multiple Myeloma Therapy. Advanced Functional Materials. 2026;36(57). doi:10.1002/adfm.202532144

BibTeX
@article{Chu2026,
  author = {Chu, Bingyang and Li, Shiqian and Wei, Xue and Wu, Xia and Yang, Peipei and Chen, Mengran and Zhang, Feng and Wang, Fangfang and Huang, Jingcao and Zhai, Xinyu and Yang, Xijing and Zheng, Yuhuan and Niu, Ting and Zhang, Kang and Qu, Ying and Qian, Zhiyong},
  title = {Bone Marrow Homing and GPRC5D‐Targeting Engineered Cell Membrane‐Camouflaged Hypoxia‐Responsive Nanoparticles for Multiple Myeloma Therapy},
  journal = {Advanced Functional Materials},
  year = {2026},
  volume = {36},
  number = {57},
  doi = {10.1002/adfm.202532144}
}
Kostenlos starten →